SCHEMBL3965067

SCHEMBL3965067

Cc1cc(Nc2cc3ccccc3c(-c3ccccc3F)n2)n[nH]1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 8/20 0.47
AURKA O14965 6/20 0.44
AURKB Q96GD4 5/20 0.44
GSK3B P49841 3/20 0.44
GSK3A P49840 2/20 0.44
SRC P12931 2/20 0.44
EIF2AK2 P19525 1/20 0.44
NTRK3 Q16288 1/20 0.43
NTRK2 Q16620 1/20 0.43
PLK4 O00444 1/20 0.43
PAK4 O96013 1/20 0.43
ITK Q08881 1/20 0.43
JAK2 O60674 2/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2C8 P10632 2/20 0.42
CYP2C9 P11712 2/20 0.42
JAK1 P23458 2/20 0.42
TYK2 P29597 2/20 0.42
CYP2C19 P33261 2/20 0.42
JAK3 P52333 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3969451 0.90 NTRK1 (0.50) NTRK1AURKAAURKBGSK3BGSK3A
SCHEMBL3967982 0.86 AURKA (0.49) NTRK1AURKAAURKBGSK3BSRC
SCHEMBL3966791 0.86 AURKA (0.47) NTRK1AURKAAURKBGSK3BSRC
SCHEMBL3972195 0.84 AURKA (0.43) NTRK1AURKAAURKBGSK3BGSK3A
SCHEMBL3965166 0.83 AURKA (0.49) NTRK1AURKAAURKBGSK3BSRC
SCHEMBL3964345 0.83 NTRK1 (0.49) NTRK1AURKAAURKBGSK3BGSK3A
SCHEMBL3972670 0.83 AURKA (0.51) AURKAAURKBGSK3BGSK3ASRC
SCHEMBL3964487 0.83 AURKA (0.53) NTRK1AURKAAURKBGSK3BGSK3A
SCHEMBL3972143 0.82 AURKA (0.56) AURKAAURKBGSK3BGSK3ASRC
SCHEMBL3961734 0.81 AURKA (0.51) NTRK1AURKAAURKBGSK3BGSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572809-B2 Isoquinoline aminopyrazole derivatives HOFFMANN-LA ROCHE INC. (US) 2009-08-11 US claimed
EP-1966190-A1 ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER F.HOFFMANN-LA ROCHE AG (CH) 2008-09-10 EP claimed
US-20070179151-A1 Isoquinoline aminopyrazole derivatives F. HOFMANN-LA ROCHE AG (CH) 2007-08-02 US claimed
WO-2007071348-A1 ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2007-06-28 WO claimed
US-7572809-B2 Isoquinoline aminopyrazole derivatives HOFFMANN-LA ROCHE INC. (US) 2009-08-11 US disclosed
US-7572809-B2 Isoquinoline aminopyrazole derivatives HOFFMANN-LA ROCHE INC. (US) 2009-08-11 US disclosed
US-7572809-B2 Isoquinoline aminopyrazole derivatives HOFFMANN-LA ROCHE INC. (US) 2009-08-11 US disclosed
EP-1966190-A1 ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER F.HOFFMANN-LA ROCHE AG (CH) 2008-09-10 EP disclosed
US-20070179151-A1 Isoquinoline aminopyrazole derivatives F. HOFMANN-LA ROCHE AG (CH) 2007-08-02 US disclosed
US-20070179151-A1 Isoquinoline aminopyrazole derivatives F. HOFMANN-LA ROCHE AG (CH) 2007-08-02 US disclosed
US-20070179151-A1 Isoquinoline aminopyrazole derivatives F. HOFMANN-LA ROCHE AG (CH) 2007-08-02 US disclosed
WO-2007071348-A1 ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2007-06-28 WO disclosed
WO-2007071348-A1 ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2007-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179151-A1 Isoquinoline aminopyrazole derivatives CYP3A5, CYP3A43, CYP3A4 NTRK1 4316/4885AURKA 1165/4885AURKB 1334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.